VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02) by Feliu, Jaime et al.
1008 |    Cancer Medicine. 2020;9:1008–1016.wileyonlinelibrary.com/journal/cam4
Received: 10 September 2019 | Revised: 5 November 2019 | Accepted: 6 November 2019
DOI: 10.1002/cam4.2722  
O R I G I N A L  R E S E A R C H
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, 
panitumumab and radiotherapy treatment in nonmetastatic 
squamous cell carcinomas of the anal canal (GEMCAD 09-02)
Jaime Feliu1  |   Rocio Garcia-Carbonero2,3 |   Jaume Capdevila4  |   
Inmaculada Guasch5 |   Vicente Alonso-Orduna6 |   Carlos Lopez7 |   Pilar Garcia-Alfonso8 |   
Carmen Castanon9 |   Isabel Sevilla10 |   Laura Cerezo11 |   Carles Conill12 |   
Begona Quintana-Angel13 |   Maria E. Sanchez14 |   Ismael Ghanem1 |    
Marta Martin-Richard15 |   Miriam Lopez-Gomez16 |   Ana Leon17 |   Monica Caro18 |   
Teresa Fernandez19 |   Joan Maurel20
1Department of Medical Oncology, CIBERONC, Catedra UAM-AMGEN, Hospital Universitario La Paz, Madrid, Spain
2Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain
3Department of Medical Oncology, imas12, UCM, CNIO, CIBERONC, Hospital Universitario 12 de Octubre, Madrid, Spain
4Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain
5Department of Medical Oncology, Hospital Althaia-Manresa, Manresa, Spain
6Department of Medical Oncology, Instituto de Investigacion Sanitaria de Aragon, Hospital Universitario Miguel Servet, Zaragoza, Spain
7Department of Medical Oncology, Hospital Universitario Marques de Valdecilla, Santander, Spain
8Department of Medical Oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain
9Department of Medical Oncology, Hospital Virgen Blanca, Leon, Spain
10Investigacion Clinica y Traslacional en Cancer, Instituto de Investigaciones Biomedicas de Malaga (IBIMA), Hospitales Universitarios Regional y Virgen 
de la Victoria, Malaga, Spain
11Department of Radiation Oncology, Hospital Universitario de La Princesa, Madrid, Spain
12Department of Radiation Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
13Department of Radiation Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain
14Department of Oncology, Hospital Universitario La Paz, Madrid, Spain
15Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
16Department of Medical Oncology, Hospital Universitario Infanta Sofia, Madrid, Spain
17Department of Medical Oncology, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
18Department of Radiation Oncology, ICO Badalona, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
19Department of Medical Oncology, Hospital Son Llatzer, Palma de Mallorca, Spain
20Department of Medical Oncology, Hospital Clinic, Translational Genomics and Targeted Therapeutics in Solid Tumours Group, IDIBAPS, University of 
Barcelona, Barcelona, Spain
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
brought to you by COREView metadata, citation and similar papers at core.ac.uk
provided by REPISALUD
   | 1009FELIU Et aL.
Correspondence
Jaime Feliu, Servicio de Oncología 
Médica, Hospital Universitario La Paz, 




This work was supported by Amgen S.A.
1 |  INTRODUCTION
Anal cancer is a relatively rare cancer which tends to be 
neglected. However, in 2008 the approximate number 
of cases was estimated to be 27 000 worldwide.1,2 In the 
United States (US), by 2018, anal cancer or anorectum can-
cer was expected to account for approximately 2.7% of all 
digestive cancers.1,2
The combination of 5-fluorouracil (5-FU), mitomycin-C 
(MMC), and radiotherapy (RT) has been established as the 
standard of care in Europe and the United States since the 
1970s.2,3 This treatment achieves a 5-year overall survival 
(OS) rate of 70%-80%,4,5 and is particularly effective in cT1/
T2 tumors achieving long lasting complete tumor regression 
in 80%-90% of cases. However, in more advanced anal can-
cers (T3-4 or N+), the 3-year OS rate is 70% and disease-free 
survival (DFS) rate is around 50%.6 In recent years, several 
strategies have been studied to improve these results, such as 
adding induction or consolidation chemotherapy, increasing 
the RT boost dose or replacing MMC with cisplatin during 
chemoradiotherapy.4,5,7 The substitution of MMC for cis-
platin is accepted in the clinic, as similar results have been 
observed for both treatments with less myelotoxicity.2,5 
Additionally, capecitabine has been considered as an alterna-
tive to infused 5-FU.2,3 However, 5-FU/MMC + RT remains 
as the standard of care.
Squamous cell carcinoma of the anal canal (SCCAC), 
has been associated with many risk factors, most impor-
tantly with human papilloma virus (HPV) infection.8-14 The 
HPV-associated E5 protein amplifies the mitogenic sig-
nals through the epidermal growth factor receptor (EGFR) 
which is broadly expressed in squamous cell carcinomas 
such as those from anogenital tract and oropharynx.15-17 
Panitumumab and cetuximab are currently the two mono-
clonal anti-EGFR antibodies more widely developed in the 
clinic. Both anti-EGFR antibodies are potential treatments 
for SCCAC patients as not only 80%-90% of SCCAC tu-
mors express EGFR, but also <5% present KRAS mutations, 
Abstract
Aim: VITAL, a phase II single-arm study, aimed to evaluate efficacy and safety 
of panitumumab addition to 5-fluorouracil (5-FU), mitomycin-C (MMC) and radio-
therapy (RT) in patients with localized squamous cell carcinoma of the anal canal 
(SCCAC).
Methods: Adult, treatment-naïve SCCAC patients (Stage T2-T4, any N, M0) and 
ECOG-PS ≤2, received panitumumab (6 mg/kg, day 1 and Q2W; 8 weeks), 5-FU 
(1000 mg/m2/d, days 1-4 and 29-32), MMC (10 mg/m2, days 1 and 29) and RT 45 Gy 
(1.8  Gy/fraction) to the primary tumor and mesorectal, iliac and inguinal lymph 
nodes, plus 10-15 Gy boost dose to the primary tumor and affected lymph nodes. The 
primary objective was disease free survival rate (DFS) at 3-years (expected 3-year 
DFS rate: 73.7 ± 12%).
Results: Fifty-eight patients (31 women; median age: 59 years; ECOG-PS 0-1:98%; 
TNM II [29%] (T2 or T3/N0/M0)/IIIA (T1-T3/N1/M0 or T4/N0/M0) [21%]/IIIB (T4/
N1/M0 or any T/N2 or N3/M0) [47%]/nonevaluable [4%]) were included. The me-
dian follow-up was 45 months. The 3-year DFS rate was 61.1% (95% CI: 47.1, 72.4). 
The 3-year overall survival rate was 78.4% (95% CI: 65.1, 87.1). Eighteen patients 
(31.0%) required a colostomy within 2 years posttreatment. Grade 3-4 toxicities were 
experienced by 53 (91%) patients. Most common grade 3-4 treatment-related events 
were radiation skin injury (40%) and neutropenia (24%). No toxic deaths occurred. 
Improved efficacy in colostomy-free survival and complete response rate was ob-
served in human papilloma virus positive patients.
Conclusions: Panitumumab addition to MMC-5FU regimen in SCCAC patients in-
creases toxicity and does not improve patients’ outcomes. RT plus MMC-5FU re-
mains the standard of care for localized SCCAC patients.
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which are associated with lack of activity in monoclonal 
anti-EGFR antibodies.17
In addition, RT can induce EGFR expression in cancer 
cells, resulting in acquired resistance. Anti-EGFR antibod-
ies might help overcome this resistance.18 Though there have 
been previous studies assessing the addition of cetuximab to 
RT regimens in nonmetastatic SCCAC patients, no studies 
have been performed to date evaluating the addition of pa-
nitumumab.19-22 In addition, previous studies have used che-
motherapy regimens based on cisplatin-5-FU combinations, 
although the combination with MMC-5-FU is still considered 
standard by many authors.23 This study aimed to evaluate the 
efficacy and safety of the addition of panitumumab to 5-FU, 
MMC and RT standard treatment in patients with SCCAC.
2 |  MATERIAL AND METHODS
Extended methodological details are provided in the 
Supplementary material. This phase II, open-label, multicentre, 
single-arm trial was conducted in 25 centers in Spain (VITAL 
Study [GEMCAD-09-02], clini caltr ials.gov: NCT01285778, 
EudraCT Number: 2010-018430-48). The study was conducted 
in accordance with the ethical principles of the Declaration of 
Helsinki and Good Clinical Practice guidelines. The ethics 
committee at each participating centre and local authorities 
approved the study protocol and its amendments. All patients 
provided written informed consent prior to study entry.
2.1 | Eligibility criteria
Patients were required to have histologically or cytologically 
confirmed SCACC with T2-T4 stage and any N stage; age 
≥18  years; Eastern Cooperative Oncology Group perfor-
mance status (ECOG-PS) 0-2 and no prior RT or chemother-
apy for this malignancy as well as no metastasis.
2.2 | Study treatments
Patients received treatment with panitumumab (Vectibix®; 
Amgen) 6  mg/kg intravenously (IV) on day 1 and every 
2 weeks for 8 weeks. Panitumumab treatment was followed 
by 5-FU 1000 mg/m2/d by continuous IV infusion on days 
1-4 and 29-32, and MMC 10 mg/m2 IV on days 1 and 29. RT 
was given on days 1-37 to a total dose of 45 Gy (1.8 Gy/frac-
tion, 5 fractions per week) to the primary tumor and meso-
rectal, iliac and inguinal lymph nodes, plus a boost dose of 
10-15  Gy to the primary tumor and affected lymph nodes. 
Intensity modulated radiation therapy or 3-D conformal RT 
was used depending on the center's availability following 
protocol guidelines (Figure S1).
2.3 | Study outcomes
The primary outcome measure in this study was DFS rate 
at 3 years. Secondary outcomes included: complete response 
(CR) rate, local-regional failure (LRF) free rate, distant fail-
ure free rate, cumulative rate of colostomy, colostomy free 
survival (CFS), recurrence free survival (RFS), OS and 
safety profile of this combination. Safety profile included the 
incidence and severity of adverse events (AE) and significant 
changes in analytical parameters.
2.4 | Statistical considerations
A sample size of 58 patients with stage ≥T2N0 was cal-
culated in order to have 80% power to detect a relative in-
crement of 3-year DFS rate of 10% compared to the US 
Gastrointestinal Intergroup Radiation Therapy Oncology 
Group (RTOG) 98-11 (3-year DFS rate  =  68%), and ac-
counting for a dropout rate of 10%. Therefore, the expected 
3-year DFS for this study was 73.7 ± 12% in order to obtain 
a relative increase of 10% compared to the RTOG 98-11.24
Detailed information on efficacy outcomes and their re-
porting are provided in the Supplementary material.
3 |  RESULTS
3.1 | Patient characteristics
A total of 58 patients were enrolled between the January 24, 
2011 and the December 2, 2013. All of them were included 
in the intention-to-treat, per-protocol and safety populations 
(Figure 1). The overall patient population had a median 
age of 59.2 (range 33.0-83.0) years and 53.5% were female 
(Table 1). A high percentage of tumors was HPV positive 
(84.8%), whereas only 9% of the patients were human im-
munodeficiency virus (HIV) positive (percentages calculated 
over assessed values, tumor samples of 13 patients and 12 
patients were not evaluable for HIV and HPV, respectively). 
Thirty-six patients (62%) had a primary tumor of ≤5 cm in 
diameter (T1 or T2) versus 20 (34.5%) who had one of >5 cm 
(T3 or T4). Thirty-nine (67%) had positive lymph nodes. The 
most common TNM tumor stage was IIIB (T4/N1/M0 or any 
T/N2 or N3/M0) (46.6%) (Table 1).
3.2 | Treatment administration
Information regarding panitumumab and chemotherapy rela-
tive dose intensity, as well as RT administration, are summa-
rized in Table S1. A total of 56 (97%) patients received the two 
programmed chemotherapy cycles. Most patients received mean 
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≥90% of the intended dose intensity of panitumumab, MMC and 
5-FU. Dose modifications were required in 9 patients (15.5%) 
for panitumumab, in 15 patients (25.9%) for 5-FU and in 11 pa-
tients (19.0%) for MMC. Regarding panitumumab: 7 patients 
(12.1%) had a dose reduction, 17 patients (29.3%) had a dose 
delay and 16 patients (27.6%) required drug discontinuation. A 
total of 23 patients received a radiation treatment break due to 
toxicity with a mean (SD) duration break of 4.9 (4.4) days.
3.3 | Overall safety
All patients in the study suffered at least one panitumumab-, 
chemotherapy- and/or RT-related AE (N  =  58). A total of 
55 patients (94.8%) developed a grade 3-4 treatment-related 
AE. The most common, occurring in ≥10% of patients, grade 
3-4 treatment-related AEs are summarized in Table 2. These 
AEs included: radiation skin injury in 39.7% (31.0% grade 3, 
8.6% grade 4), diarrhea in 20.7% (20.7% grade 3, 0% grade 
4), neutropenia in 24.1% (19.0% grade 3, 5.2% grade 4), 
leukopenia in 10.3% (10.3% grade 3, 0% grade 4) and lym-
phopenia in 15.5% (13.8% grade 3, 1.7% grade 4). A total of 
21 (36.2%) patients reported a serious AE (SAE) related to 
panitumumab, chemotherapy and/or RT. The most common 
SAEs, occurring in ≥5% of patients included, were: febrile 
neutropenia in 6.9%, radiation skin injury in 6.9%, diarrhoea 
in 6.9%, neutropenia in 5.2% and proctalgia in 5.2%. Sixty-
nine percent of patients presented a hematological toxicity 
(53.4% grade 3-4) and 77.6% presented diarrhea or colitis 
(22.4% grade 3-4) throughout the study. Furthermore, 55.1% 
of patients presented a skin rash (3.4% grade 3-4). AEs of 
special interest are detailed in Table S2.
3.4 | Primary outcome: 3-year DFS
The median follow-up time was 45  months (range 3-67). 
Treatment efficacy results are summarized in Table 3. The 
DFS rate at 3 years (95% CI) was 61.1% (47.1, 72.4). Hence, 
the expected 3-year DFS rate of 73.7 ± 12% was not achieved 
(Figure 2).
3.5 | Secondary outcome: OS, CR, LRF, 
distant metastases, and colostomy
The OS at 3  years was 78.4% (95% CI: 65.1, 87.1). The 
median OS and DFS were not reached. One patient was co-
lostomized prior to his/her study entry. Eighteen patients 
(31.0%) required a colostomy at some point throughout the 
F I G U R E  1  Patient disposition flow chart
End panitumumab (n = 18)
Unacceptable toxicity (n = 16)
Non-related AE (n = 1)
Withdraw of IC (n = 1)
End chemotherapy (n = 11)
Unacceptable toxicity (n = 9)
Non-related AE (n = 1)
Withdraw of IC (n = 1)
End radiotherapy (n = 6)
Unacceptable toxicity (n = 5)
Non-related AE (n = 1)
End of Study:
Per protocol (n = 37)
Withdraw of IC (n = 1)
Lost to follow up (n = 3)
Exitus (n = 12)
Other (n = 5)
Enrolled patients (n = 58)
Screened patients (n = 65)
Completed radiotherapy 
treatment (n = 52)
Completed chemotherapy 
treatment (n = 47)
Completed panitumumab 
treatment (n = 40)
Excluded (n = 7):
Did not meet inclusion criteria (n = 4)
Refused to participate (n = 1)
Other (n = 2)
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study because of anal cancer (N = 17, 94.4%) and poor ano-
rectal function (N = 1, 5.6%). The CFS rate at 3 years was 
68.1% (95% CI: 54.2, 78.6).
The CR rate was 81.0% (95% CI: 69.8, 92.2) (N = 47) 
(Figure S2). Eighteen patients (31.0%) showed only a LRF, 
two patients (3.4%) showed a local-regional and distant fail-
ure and two patients (3.4%) showed only distant failure. The 
LRF free and the distant failure free rates at 3  years were 
64.8% (95% CI: 50.9, 75.7) and 93.0% (95% CI: 82.4, 97.3), 
respectively. Taking into account only patients with CR (i.e., 
47 patients): 75.8% (95% CI: 60.5, 85.8) of patients were re-
currence-free at 3 years.
3.6 | Univariate and multivariable analyses
No significant associations were observed between baseline 
characteristics (age, sex, ECOG status, primary tumor size, 
HPV, HIV, and cancer stage) or rash severity and the DFS 
and OS outcomes (Tables S3-S7).
A statistically significant association was observed be-
tween: (a) CFS in HPV negative (N = 7, mean [SD] = 7.6 
[0.6]) vs HPV positive (N  =  39, 17.3 [0.6]) patients 
(P  =  .0277), (b) distant failure free rate in HIV negative 
(N = 41, mean [SD] = 3.6 [-]) vs HIV positive (N = 4, [-]) pa-
tients (P = .0240) and (c) CR rate in HPV positive (N = 39, 
84.6% [95% CI 73.3, 95.9]) vs HPV negative (N = 7, 28.6% 
[95% CI 0.0, 62.1]) patients (P < .05) (Figure S3). However, 
most subpopulations sample sizes were small.
DFS and OS were not associated with any of the prognos-
tic factors studied using a multivariable analysis. All patients 
were wild type for RAS and EGFR, so it was not possible 
to evaluate treatment outcomes according to RAS and EFGR 
mutation status.
4 |  DISCUSSION
The results of this study show that panitumumab, when added 
to MMC-5FU-based chemoradiation, does not improve 
outcomes for the treatment of patients with nonmetastatic 




Median (range) age, year 59.2 (33.0-83.0)
Sex, female, N (%) 31 (53.5)
Ethnicity, Caucasian, N (%) 57 (98.3)










HIV positivea, N (%) 4 (8.9)
HPV positivea, N (%) 39 (84.8)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HIV, human im-
munodeficiency virus; HPV, human papillomavirus; NE, not evaluable; TNM, 
TNM classification of malignant tumors.
aPercentage calculated over observed values (13 patients and 12 patients for the 
HIV and HPV results respectively were not evaluated). 





Grade 3-4 related AEs, N (%) 53 (91.4)
Most commonb





Serious treatment-related AE, N (%) 21 (36.2)
Most commonc
Febrile neutropenia 4 (6.9)




Abbreviations: AE, adverse events; RT, radiotherapy; SAE, serious AE.
aAEs related to panitumumab and/or chemotherapy and/or RT. 
bMost common (>10%) AE related to any of the three treatments. 
cMost common (>5%) SAE related to any of the three treatments. 




DFS rate at 3 y 61.1 (47.1, 72.4)
OS rate at 3 y 78.4 (65.1, 87.1)
CFS rate at 3 y 68.1 (54.2, 78.6)
Clinical CR rate 81.0 (69.8, 92.2)
LRF-free rate at 3 y 64.8 (50.9, 75.7)
Distant failure free rate, at 3 y 93.0 (82.4, 97.3)
RFS rate at 3 y 75.8 (60.5, 85.8)
Abbreviations: CFS, colostomy-free survival; CI, confidence interval; CR, 
complete response; DFS, disease-free survival, LRF, local-regional failure, OS, 
overall survival; RFS, recurrence-free survival.
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SCCAC stage >T1N0. More specifically, the primary objec-
tive of the study, which was to demonstrate an improvement 
in the 3-year DFS rate, was not achieved.
At the time of the study design, little data on anti-EGFR 
agents in SCCAC patients was available. However, current 
results have shown that several of the initial studies with 
cetuximab showed high rates of grade 3-4 radiation-in-
duced dermatitis and diarrhoea. Toxicity was deemed 
unacceptable and led to early discontinuation in two of 
these trials20,25 and also showed poor long-term efficacy 
results.21 Other studies with cetuximab-chemoradiation 
did not support further clinical development in phase III 
trials of cetuximab in patients with SCCAC, either due to 
small numbers,26 excessive toxicity19,22 or incomplete/in-
conclusive efficacy data.27,28 It should be noted that those 
studies testing cetuximab were conducted mainly with cis-
platin-5FU as a chemotherapy partner.19,20,25 Our study was 
the first to investigate the combination of panitumumab 
with MMC-5FU-RT. After our study commenced, the re-
sults of a phase I study aiming to determinate the maximum 
tolerated dose of panitumumab and 5-FU when combined 
with MMC-RT was published. The recommended doses 
were 3 mg/kg and 400 mg/m2, respectively,29 considerably 
lower than the doses used in this study. Also, Aparicio et al 
communicated the preliminary results of a phase II study 
that included 45 patients using this scheme. Despite this 
dose reduction, 89% and 38% of the patients reported a 
grade 3 or grade 4 toxicity, respectively. With a median 
follow-up of 18 months, the RFS and CFS were of 72% and 
78%, respectively.30
Data from head and neck studies show that toxicity induced 
by RT associated with cetuximab has a marked inflamma-
tory component, a fact that may have contributed to the poor 
tolerability of regimens with chemoradiation and cetuximab, 
associated with unacceptable rates of acute radiation-induced 
inflammatory grade 3-4 AEs. The results of our study would 
suggest that this tolerability issue is less marked for panitu-
mumab, although the non-randomized comparison prevents 
us from drawing any definitive conclusions. In this study, the 
investigational treatment with panitumumab has resulted in 
substantial but acceptable and manageable toxicity. Less than 
18% of patients presented grade 3-4 rash. Concerning the 
most important toxicities such as radiation-induced epitheli-
tis, diarrhea, and neutropenia, no significant increase in grade 
3-4 AEs compared to what was expected from treatment with 
MMC-5FU-RT was observed.
F I G U R E  2  Kaplan-Meier estimates 
of disease free survival (A) and overall 
survival (B)






Subjects Event Censored Median (95%CI)
58 37.9% (22) 62.1% (36) NR (16.6, NR)
3-y DFS rate = 61.1% (95%CI: 47.1 - 72.4) 










58 52 38 34 33 32 28 24 14No. at risk






Subjects Event Censored Median (95%CI)
58 22.4% (13) 77.6% (45) NR (NR, NR)
3-y OS rate = 78.4% (95%CI: 65.1-87.1)
Months from first treatment dose
58 57 53 50 40 34 22 1 0No. at risk
6 24 42 60
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In the multivariable analysis looking for predictive fac-
tors, none of the variables included was associated with DFS 
or OS. Although no association was found, to the authors' 
knowledge, this is the first time that the association between 
skin rash and efficacy has been addressed in patients with 
SCCAC. This result is not consistent with what has been 
observed in patients with other solid tumors (i.e., colorectal 
adenocarcinoma), in whom skin rash severity is associated 
with improved efficacy of anti-EGFR agents.31 In the mul-
tivariable analysis of CR (81% for the whole population), 
no association with skin rash severity was observed either. 
However, a remarkable result was found concerning the 
HPV status. Improved efficacy was observed both in terms 
of CFS and CR rate in patients with HPV-positive tumors. 
Due to the design of the study, it is not possible to determine 
whether this was a predictive or prognostic factor of panitu-
mumab-MMC-5FU-RT efficacy. However, these results are 
in line with those observed in patients with squamous cell 
carcinoma of the oropharynx who have a better prognosis if 
they are HPV-positive. In these cases, the possibility of ther-
apeutic de-escalation has been suggested.32 The extrapola-
tion of this concept to patients with HPV-positive SCCAC is 
still unknown and could only be confirmed in further larger 
studies. However, two recent randomized trials have studied 
this strategy in HPV-positive patients with oropharyngeal 
cancer, concluding that, besides cetuximab resulting in lesser 
toxicities when administered with RT compared with cispla-
tin + RT, it was found to be inferior in OS.33,34 These results 
suggest that de-escalation strategy should be carefully used in 
clinical practice, and also that anti-EGFR antibodies may not 
be the optimal therapies for this strategy.
The reason behind the lack of incremental efficacy when 
anti-EGFR is added to chemo-radiotherapy in SCCAC pa-
tients remains unknown. Classically, the RAS and EGFR 
mutations have been appointed as factors of resistance to an-
ti-EFGR therapies, but in our study no patient presented with 
these mutations.
It could be the case that EGFR downstream mutations (ie, 
activating in PIK3CA, inactivating in PTEN) might mediate 
resistance to EGFR-targeted therapies, being more frequent 
in HPV-positive oropharyngeal carcinoma.35 Actually, some 
retrospective studies in head and neck tumors suggest that 
anti-EGFR treatments might be more efficacious in VPH-
negative tumors.36 Additionally, it has been described that 
FBXW7 mutations are associated with anti-EGFR resis-
tance.37 Finally, it is noteworthy that, besides initial studies 
suggest an 80%-90% EGFR overexpression rate in SCCAC 
tumors,16,17 a recent meta-analysis suggests that this may 
occur in only 60%, which may be associated with a lower 
sensitivity to anti-EGFR therapies.38
The two monoclonal antibodies (mAb) cetuximab and pa-
nitumumab are often considered equally effective and their se-
lection for clinical use is often a matter of personal choice in 
colorectal cancer. Yet they are different. Cetuximab is an immu-
noglobulin G1 isotype mAb, which can elicit immune functions 
such as antibody-dependent cell-mediated cytotoxicity involv-
ing natural killer cells, T-cell recruitment, and T-cell priming. 
There is evidence that this process can lead to immunosuppres-
sive feedback loops,39 and some have therefore suggested com-
bining checkpoint inhibitors with cetuximab or cobimetinib in 
microsatellite stable colorectal cancer. Panitumumab, an IgG2 
isotype mAb, is not reported to exert these immune effects.
Therapies targeting PD-1/L1 have produced response 
rates of 15%-20% in patients with HPV associated cancers 
including cervical, anal or head and neck squamous cell car-
cinoma. Another potential target for these diseases is trans-
forming growth factor-β (TGF-β) as genome wide association 
studies in HPV-positive cancers have shown TGF-β to be sig-
nificantly overexpressed.40
The nonrandomized design is the main limitation of 
this study as it can be associated with a selection bias. It is 
worth mentioning that male sex and advanced stage have 
been shown to be poor prognostic markers for LRF and 
OS.3,4 In our study, we included a percentage of men (46%) 
higher than those found in previous studies which are close 
to 25%-30%,7,19,24-26 and a higher percentage of patients with 
positives nodes (67%) and with stage IIIB (47%) than those 
found in previous studies which are close to 30%-35%.4,5 
Therefore, our population may be biased toward poor progno-
sis. However, the phase II design was mandatory as this study 
is the first conducted and reported, assessing the efficacy and 
toxicity of panitumumab associated with MMC-5FU-based 
chemoradiation in patients with SCCAC.
It is necessary to continue investigating with new RT 
techniques and new pharmacological strategies such as im-
munotherapy with anti-PD-1 mAbs,41 therapeutic vaccines 
targeting the E6 and E7 oncoproteins,42 PIK3CA mutant 
targeted therapies (present in 15%-20% SCCAC tumors), or 
drugs targeting TGF-β.40
5 |  CONCLUSIONS
The addition of panitumumab to the standard chemoradiation 
regimen with MMC-5FU in patients with SCCAC did not 
result in improved outcomes.
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